Sanford Burnham Prebys Medical Discovery Institute

The Scripps Research Institute

La Jolla Cancer Research Foundation

Sanford-burnham Medical Research Institute

The Burnham Institute

Burnham Institute for Medical Research

Elena B Pasquale

Mitchell Koolpe

Philip E Dawson

Erika Olson

Keith K Murai

Fereydoun G Sajjadi

Stefan J Riedl

Philip Dawson

Disclosed herein are methods and compositions engineered to modulate EphA2, including novel peptides with unexpectedly high specificity and binding affinity. The compositions described herein can be attenuated to treat subjects suffering from diseases and/or conditions.

Nanomolar peptides and derivatives to differentially modulate ephrin receptors

The present specification discloses APY cyclic peptides having EphA4 antagonistic activity, pharmaceutical compositions containing such EphA4 antagonists, and methods and uses of treating an EphA4-based disease, disorder or pathology in an individual using such APY cyclic peptides or pharmaceutical compositions.

EPHA4 cyclic peptide antagonists for neuroprotection and neural repair

Novel agents are described that bind to Eph receptors. Methods of using these agents to modulate the activity of Eph receptors, stimulate apoptosis, and deliver therapeutic agents are also described. Methods of screening for agents capable of selectively binding to Eph receptors are also described.

Agents that modulate Eph receptor activity

The application is related to the identification of peptides that selectively bind to Eph receptors of the B class. Also disclosed are uses of such peptides in the treatment of a variety of diseases. Additionally, imaging tumors in patients is described by administrating labeled peptides to patients and then obtaining an image of the labeled peptides.

EphB receptor-binding peptides

The invention is directed to substantially purified Eph-related protein tyrosine kinases, or functional fragments thereof, having about 23 to 66 percent amino acid sequence identity in their carboxyl terminal variable regions compared to known members of the Eph subclass of tyrosine kinases. Nucleic acids encoding such Eph-related protein tyrosine kinases, vectors and host cells are also provided. The invention is also directed to a method of diagnosing cancer and determining cancer prognosis. The method includes removing a tissue or cell sample from a subject suspected of having cancer and determining the level of Eph-related protein tyrosine kinase in the sample, wherein a change in the level or activity of a Eph-related protein tyrosine kinase compared to a normal sample indicates the presence of a cancer or indicates the level of malignancy of a cancer.

Growing community of inventors

San Diego, CA, United States of America

Elena B Pasquale